A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. [artículo]
Por: Brandariz Castelo, José Antonio [Otorrinolaringología]
| Hitt Sabag, Ricardo [Oncología Médica].
Colaborador(es): Servicio de Otorrinolaringología | Servicio de Oncología Médica.
Editor: Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 2014Descripción: 25(1):216–225.Recursos en línea: Solicitar documento Resumen: Concurrent chemoradiotherapy (CCRT) is the standard treatment for patients with unresectable, nonmetastatic locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN). This randomized, open-label, phase III clinical trial compared the efficacy between standard CCRT and two different induction chemotherapy (ICT) regimens followed by CCRT.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC895 (Navegar estantería) | Disponible |
Formato Vancouver:
Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A et al. Spanish Head and Neck Cancer Cooperative Group (TTCC). A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014 Jan;25(1):216-25.
PMID: 24256848
Contiene 15 referencias
Concurrent chemoradiotherapy (CCRT) is the standard treatment for patients with unresectable, nonmetastatic locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN). This randomized, open-label, phase III clinical trial compared the efficacy between standard CCRT and two different induction chemotherapy (ICT) regimens followed by CCRT.
No hay comentarios para este ejemplar.